584 Phase I/II study to evaluate the safety and tolerability of avelumab in combination with other anti-cancer therapies in patients with advanced malignancies

• Aung Naing,
• Funda Meric-Bernstam,
• Shubham Pant,
• Milind Javle,
• Juhee Song,
• Anas Alshawa,
• Bettzy Stephen,
• Abdulrazzak Zarifa,
• Jordi Rodon,
• Yali Yang,
• Robert A Wolff,
• Anne Knisely,
• Van Morris,
• Jibran Ahmed

Affiliations

Aung Naing

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Funda Meric-Bernstam

2The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Shubham Pant

MD Anderson Cancer Center, Houston, TX, USA

Milind Javle

Aff11 grid.240145.60000000122914776MD Anderson Houston TX USA

Juhee Song

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Anas Alshawa

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Bettzy Stephen

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Abdulrazzak Zarifa

Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Jordi Rodon

Department of Investigational Cancer Therapeutics (Phase 1 Program), The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Yali Yang

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Robert A Wolff

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Anne Knisely

6College of Physicians and Surgeons, Columbia University; Obstetrics and Gynecology

Van Morris

2MD Anderson Cancer Center, Houston, TX, USA

Jibran Ahmed

The University of Texas MD Anderson Cancer Center, Houston, TX, USA